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A mouse monoclonal antibody (mAb) was developed against monohexaosylceramtde This mAb dtfferenttally reacted on thm-layer chromatograms 
wtth 3 types of galactosylceramtde (GalCer) obtained from bovme bram Structural analysts of the 3 glycohptds revealed that they consisted of 
the same galactose and sphmgosme but of apparently dtfferent fatty actds Among the 3 GalCers, the mAb reacted with two GalCers which con- 
tamed a-hydroxy fatty actds, but not wtth GalCer composed of nonhydroxy fatty acids These findings suggest not only that the mAb dtscnmmated 
the fatty actd composttton m the ceramtde moiety of GalCer, but also that the ceramtde structure defines the tmmunologtcal epttope as tt 1s known 
to do for the carbohydrate motety of glycosphmgohptd 
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1. INTRODUCTION 
Glycosphingolipids (GSL) which are present on the 
surfaces of animal cells have been well characterized 
structurally despite their molecular diversity [l-3]. 
These molecules are known to be involved in many 
membrane functions, such as those associated with cell 
growth, ontogenesis, differentiation and malignant 
transformation [l]. Furthermore, when added ex- 
ogenously, they show potent biological activities in 
vitro or in vivo [4]. The advent of the monoclonal an- 
tibody (mAb) has produced much more knowledge of 
and attention to GSL [5,6]. Interestingly, most mAbs 
to GSL, when produced by immunization with cells or 
purified molecules as antigens, react with the nonreduc- 
ing termini of the carbohydrate structures of GSL. 
In the present report, we describe a mouse mAb 
which recognizes the rmmunologrcal epitope composed 
of both carbohydrate and ceramide moieties of galac- 
tosylceramrde. 
2. MATERIALS AND METHODS 
2 1. Productron of mAb 
The mAb was generated as described previously [7]. In brief, 
BALB/c mice were immumzed with cultured human pancreatic 
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cancer cells, designated as SUIT-2 The mAb-producmg hybrtdomas 
were prepared by fusion of splemc cells from tmmumzed mice and the 
mouse myeloma cell line, P3X63-AG-8-UI Hybrtdomas were further 
propagated in mtce as mtraperttoneal tumors The culture superna- 
tant from the hybridomas or the ascttes from tumor-bearmg mice was 
used for tmmunologtcal assays. 
2.2. Preparation of GSL 
GSL of SUIT-2 cells and standard glycohptds from bovme brain 
which was often used as a source of reference GSL were prepared as 
reported previously (81. In brief, glycohptds were isolated by extrac- 
tion with organic solvent and subsequent mild alkaline hydrolyses 
Glycohptds were then separated mto neutral and acidic fractions by 
DEAE-Sephadex A-25 column chromatography Each GSL was fur- 
ther punfted by Iatrobeads column chromatography. 
2 3 TLC and TLC-immunostarnmg 
Purified GSL were analyzed by TLC performed wtth a solvent 
system of chloroform/methanol/water (60:40: 10, v/v) and vtsuahz- 
ed with orcmoVHzS04 reagent which rdenttftes the carbohydrates in 
GSL [8]. The tmmunoreacttvtty of the mAb with GSL was exammed 
by TLC-tmmunostammg, as descrtbed previously [9] 
2 4 Elucrdatlon of precrse structure of CMH 
The composmons of the carbohydrate, fatty acid, and sphmgosme 
components of CMH from bovine bram were determined by TLC, 
gas-hqtud chromatography (GLC), and fast atom bombardment 
mass spectrometry (FAB-MS) as reported prevtously [8,10] 
3. RESULTS AND DISCUSSION 
A mAb (IgM subclass) was produced by one of 26 
hybridomas which reacted with SUIT-2 cells and were 
partly described previously [7]. Since trypsin digestion 
did not alter the reactivity of the mAb with SUIT-2 cells 
(data not shown), we purified GSL from the cells to 
characterize the immunoreactive antigen. Fig. 1 shows 
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both the TLC of OS.. uisuaIk%?d witfl oz-&mi r&gent 
(lane 1) and TLC~i~m~nost~in~ with the mAb (lane 
2). The mAb immunologically labeled only one of the 
orcinol-positive bands (lane 2 in fig. I). The labeled 
band appeared to be B CMH from its mobility on the 
TLC plate compared with the reference GSLs from 
bovine brain (data nut shown). The bust of im- 
m~noIogi~~I~ labeled GSL in the cells, however, was 
not great enough for structural anlrlysis. We next ex- 
amined the immunoreactivity of the mAb with stan- 
dard CMH purified from bovine brain, Purified CMH 
&owed 3 orc~oI~~s~~~ bands (two major bands and 
one minor band) on a TLC pIate (lane 1 in fig.2) In- 
ter~stingly~ the mAb reacted with the lower two of the 
3 bands of CMH (clear and faint bands) by TLC- 
i~muuost~~ng (lane 2 in fig.2). There were no detec- 
table bands following nonspecific background staining 
with preimm~ne serum in lieu of the mAb (lane 3 in 
fii.2). The in~~~d~~l CMH bands were then further 
separated. Two of them were clearly isolated but the 
lower one was not separated from the middle one, as 
shown in panel D in fig.2. Panel D shows orcinol stain- 
ing of the isolated CMW, with an upper band (lane 4)), 
a middle band (lane S), and a mixtmx of middle and 
fower bands (Iane 6). Panel E in fig.2 shows the im- 
munoreactivity of the isolated bands with the mAb. 
Analysis by GLC revealed that the GSL were all 
GalCers and that there was a striking difference in the 
fatty acid compositkms (tabIe 1). The jmm~norea~t~ve 
GaICers (idle and Xower bands) were composed of LtTI- 
~~d~~xy fatty acids, whereas the immu~o~egative up-
per GalCer contained no cy-hydrorty fatty acids. The 
lower GalCer seemed to predominantly contain LT- 
hydroxy fatty acids with shorter chains as compared 
with those of the middle one. There was no difference 
in the other corn~~~~~t~ @able $1.. Tfrese findings wert: 
ftrxtber cotirmed by FAIf-MS (data ltot show@. 
&QS Q!e jrnrn~orea~y~~y of CMH from bovine kxairz, TLC 
(panels A and D), TLC-immunastaining with m&b (Panels B and E), 
and nonspecific staining with preimmune serum (panel C). (Lanes 
l-3) total CMH; (lanes 4 and 7) isolated upper b&nd of CMH; (lanes 
5 and g) middte band of CMN; (lanes 6 and 9) m~tu~ of middle an& 
lower CMH bands. 
Thus, the mAb reacted with GaICers and discrimin- 
ated the fatty acid composition in the molecules, while 
the usual mAb to GSL recognized the carbohydrate 
structures in the molecule f&6& Thus, the im- 
rn~oI~~~~y fabeled GSL from SXT-2 c&s also 
m&&t be a WCer with ac-hydrcxq fatty acids. 
The reactivity of the mAb with structurally related 
glycolipids was aIso examined as follows. Panel A in 
fig.3 shows TLC of gdactosylsphingosine which was 
Table 1 
~tru~r~l analysis of GMH purified from b~v~~~ brain by GLC 
Middle 
- 
4 
a.42 
0.62 
0.76 
69.50 
28.70 
0.1 
0.4 
2.7 
96.6 
rao.a 
0-Q 
Middle + lower 
35.80 
0.33 
3.10 
50.82 
9.a 
0.1 
0.5 
3.2 
96.2 
IQ&ID 
0.0 
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prepared from GaICer purified from hI.Im#B ~~a~~ (in- 
dicated by an arrow in sane f) and g#~act~s~~d~a~~~~- 
cerof purifi& from porcine testis (z&M? 2)* These 
GafCer ikKd~g;rBX~S W%%% BOrt, ~~M~~~~~~~~~l~ l’f!ftChF 
on a TLC p&t: (lanes 3 and 4 of panel 3 ia fi@], These 
results suggested that the ~mmunulogic~ e&ape re- 
quired both s~~i~~osi~e andin-hydroxy f&Cy acids in 
the cerarn~~~* i,e. the ceramide moiety dt$o &fined the 
irnrnunol~~~~~l epitape, as it is well knoml to da in the 
case of the sugar moiety of GSL. Furthermore, the 
mAb labeled one of the GSC from SUIT-12 cells (fig-l) 
and also 2 of the 3 GaICer of bovine brd~t (fig$% 
~tho~~b they dl contained the ceramide m&&es_ This 
reszdt s~~~~~ that r&e epitope r~~~~ the car- 
bohydrate moiety in ~dd~~~on to the ce~~~d~ with E- 
hydroxy fatty acids. 
We have reported a mouse mAb which reacted with 
2 of 3 GalCer amcrng GSL from bovine br& by TLC- 
irnrn~ost~~n~. This was of particular interest be- 
cause of being the first mAb with we~~~~~~te~~ 
a~t~~e~c de~~rn~~~ts in GaICer, and bec;ause of its 
d~scr~~nat~o~ of sr-hydroxy fatty acids from nonhy- 
droxy fatty ~~~~$ in the molecule. The mAb was 
prepared using Mornay cancer cells although G&%r has 
never been knawn to be a tumor antigen. This GSL is 
known to ‘be st ~~ffer~~tia~on marker ~~~~~~s~d on 
Schwann cells and o~igodendroc~es in nervous ystem 
[I 11. The development of this new mAb may provide 
further informative about the functions of GaICer. 
Moreover, the r&e of ~~~rox~~~t~on of the fatty acids 
of the cer~~de moiety in the ant~g~~~~ of GSL ap- 
pears zo be worth ~~~t~~~ng because the ceramide 
moiety may define the ~rnrnnno~o~c~ epitope even at 
the nomeduci~~ carbohydrate rminal of GSC [x2]. 
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